Human Papillomavirus (HPV) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, “Human Papillomavirus (HPV) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Human Papillomavirus (HPV) Therapeutics market. The report identifies the key trends shaping and driving the global Human Papillomavirus (HPV) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Human Papillomavirus (HPV) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Human Papillomavirus (HPV) Therapeutics market. Its scope includes -
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
Summary
GlobalData, the industry analysis specialist, has released its new report, “Human Papillomavirus (HPV) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Human Papillomavirus (HPV) Therapeutics market. The report identifies the key trends shaping and driving the global Human Papillomavirus (HPV) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Human Papillomavirus (HPV) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Human Papillomavirus (HPV) Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Human Papillomavirus (HPV) Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Human Papillomavirus (HPV) Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Human Papillomavirus (HPV) Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in Human Papillomavirus (HPV) Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Human Papillomavirus (HPV) Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Human Papillomavirus (HPV) Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Human Papillomavirus (HPV) Therapeutics market landscape? - Identify, understand and capitalize.
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 HPV THERAPEUTICS - INTRODUCTION
2.1 Disease Overview
2.1.1 Common warts
2.1.2 Laryngeal papilloma
2.1.3 Genital warts
2.1.4 Cervical cancer
2.2 Epidemiology
2.3 Etiology and Pathophysiology
2.4 Signs and Symptoms
2.5 Diagnosis
2.5.1 Pap smear
2.5.2 Colposcopy
2.5.3 Biopsy
2.5.4 Human papillomavirus test
2.6 Treatment and Management Options
2.6.1 Prophylactic vaccines
2.6.2 Genital Warts and common warts treatments
2.6.3 Cervical cancer treatments
2.7 GlobalData Pipeline Report Guidance
3 HPV THERAPEUTICS - MARKET CHARACTERIZATION
3.1 HPV Therapeutics Market Size (2005-2010) – Global
3.2 HPV Therapeutics Market Forecast (2010-2017) – Global
3.3 HPV Therapeutics Market Size (2005–2010) – The US
3.4 HPV Therapeutics Market Forecast (2010-2017) – The US
3.5 HPV Therapeutics Market Size (2005–2010) – France
3.6 HPV Therapeutics Market Forecast (2010–2017) – France
3.7 HPV Therapeutics Market Size (2005–2010) – Germany
3.8 HPV Therapeutics Market Forecast (2010–2017) – Germany
3.9 HPV Therapeutics Market Size (2005–2010) – Italy
3.10 HPV Therapeutics Market Forecast (2010-2017) – Italy
3.11 HPV Therapeutics Market Size (2005–2010) – Spain
3.12 HPV Therapeutics Market Forecast (2010–2017) – Spain
3.13 HPV Therapeutics Market Size (2005–2010) – The UK
3.14 HPV Therapeutics Market Forecast (2010–2017) – The UK
3.15 HPV Therapeutics Market Size (2005–2010) – Japan
3.16 HPV Therapeutics Market Forecast (2010-2017) – Japan
3.17 Drivers and Barriers for the HPV Therapeutics Market
3.17.1 Barriers for the HPV Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway
4 HPV THERAPEUTICS - COMPETITIVE ASSESSMENT
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the HPV Therapeutics Market
4.3.1 Prophylactic Vaccines
4.3.2 Comparison between Cervarix and Gardasil
4.3.3 Therapeutic Drugs
4.3.4 Aldara (imiquimod, 5%)
4.3.5 Veregen (sinecatechin)
4.3.6 Alferon N (interferon alfa-n3)
4.4 Newly Approved Drug
4.4.1 Zyclara (imiquimod, 3.75%)
5 HPV THERAPEUTICS - PIPELINE ASSESSMENT
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 HPV Therapeutics Pipeline – Pipeline by Phases of Development
5.3.1 HPV Therapeutics – Phase III Pipeline
5.3.2 HPV Therapeutics – Phase II Pipeline
5.3.3 HPV Therapeutics – Phase I Pipeline
5.3.4 HPV Market – Discovery and Pre-Clinical Pipeline
5.3.5 Technology Trends Analytic Framework
5.4 HPV Therapeutics Market – Clinical Pipeline by Mechanism of Action
5.5 HPV Therapeutics – Promising Drugs Under Clinical Development
5.6 Molecule Profile for Promising Drugs Under Clinical Development
5.6.1 V503
5.6.2 R3484
5.7 Key Takeaway
6 HPV THERAPEUTICS - CLINICAL TRIALS MAPPING
6.1 Clinical Trials by Region/Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in HPV Therapeutics Clinical Trials
7 HPV THERAPEUTICS - STRATEGIC ASSESSMENT
7.1 Key Events Impacting the Future Market
7.2 HPV Therapeutics: Implications for Future Market Competition
8 HPV THERAPEUTICS - FUTURE PLAYERS
8.1 Introduction
8.2 Company Profiles
8.2.1 Merck & Co
8.2.2 GlaxoSmithKline plc
8.2.3 F. Hoffmann-La Roche Ltd.
8.2.4 Inovio Pharmaceuticals,Inc
9 HPV THERAPEUTICS - LICENSING AND PARTNERSHIP DEALS
10 HPV THERAPEUTICS - APPENDIX
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography
LIST OF TABLES
Table 1: Types Of HPV Causing Different Diseases
Table 2: Cervical Cancer Treatment by Stage of the Disease, 2010
Table 3: HPV Therapeutics Market, Global, Revenue ($m) 2005–2010
Table 4: HPV Therapeutics Market, Global, Forecast ($m), 2010–2017
Table 5: HPV Therapeutics Market, The US, Revenue ($m), 2005–2010
Table 6: HPV Therapeutics Market, The US, Forecasts ($m), 2010–2017
Table 7: HPV Therapeutics Market, France, Revenue ($m), 2005–2010
Table 8: HPV Therapeutics Market, France, Forecasts ($m), 2010–2017
Table 9: HPV Therapeutics Market, Germany, Revenue ($m), 2005–2010
Table 10: HPV Therapeutics Market, Germany, Forecasts ($m), 2010–2017
Table 11: HPV Therapeutics Market, Italy, Revenue ($m), 2005–2010
Table 12: HPV Therapeutics Market, Italy, Forecasts ($m), 2010–2017
Table 13: HPV Therapeutics Market, Spain, Revenue ($m), 2005–2010
Table 14: HPV Therapeutics Market, Spain, Forecasts ($m), 2010–2017
Table 15: HPV Therapeutics Market, The UK, Revenue ($m), 2005–2010
Table 16: HPV Therapeutics Market, The UK, Forecasts ($m) 2010–2017
Table 17: HPV Therapeutics Market, Japan, Revenue ($m), 2005–2010
Table 18: HPV Therapeutics Market, Japan, Forecasts ($m), 2010–2017
Table 19: Gardasil Approvals and Fillings
Table 20 : Comparison Of Cervarix And Gardasil
Table 21: Zyclara, Clinical Trial Details, Complete Clearance of External Genital Warts Within 16 Weeks of Treatment (%)
Table 22: Zyclara, Clinical Trial Details, Complete Clearance of External Genital Warts Within 16 Weeks of Treatment by Gender (%), Combined Study
Table 23: HPV Therapeutics Market, Phase III Clinical Pipeline, 2010
Table 24: HPV Therapeutics Market, Phase II Clinical Pipeline, 2010
Table 25: HPV Therapeutics Market, Phase I Clinical Pipeline, 2010
Table 26: HPV Therapeutics Market, Discovery and Pre-Clinical Pipeline, 2010
Table 27: HPV Therapeutics Market, Most Promising Drugs Under Clinical Development, 2010
Table 28: HPV Therapeutics Market, Number of Clinical Trials by Country, 2010
Table 29: HPV Therapeutics Market, Number of Clinical Trials by Phase, 2010
Table 30: HPV Therapeutics Market, Number of Clinical Trials by Status, 2010
Table 31: HPV Therapeutics Market, Number of Prominent Sponsors, 2010
Table 32: HPV Therapeutics Market, Top Companies Participating in Therapeutics Clinical Trials, 2010
Table 33: Merck &Co Infectious Diseases, Pipeline, 2010
Table 34: Merck &Co, Inc – Deals
Table 35: GlaxoSmithKline Plc. – Infectious Diseases, Pipeline, 2010
Table 36: GlaxoSmithKline Plc. Deals, Alliances and Partnerships , 2010-2011
Table 37: F. Hoffmann-La Roche Ltd ,Infectious Disease Pipeline, 2010
Table 38: F. Hoffmann-La Roche Ltd Deals, Alliances and Partnerships , 2010-2011
Table 39: Inovio Pharmaceuticals –Infectious Disease, Pipeline, 2010
Table 40: Inovio Pharmaceuticals, Inc. – Deals
Table 41: HPV Therapeutics Market, Global, Deals, 2010
LIST OF FIGURES
Figure 1: Pathophysiology of HPV
Figure 2: HPV Therapeutics Market, Global, Revenue ($m), 2005–2010
Figure 3: HPV Therapeutics Market, Global, Forecasts ($m), 2010–2017
Figure 4: HPV Therapeutics Market, The US, Revenue ($m), 2005–2010
Figure 5: HPV Therapeutics Market, The US, Forecasts ($m), 2010–2017
Figure 6: HPV Therapeutics Market, France, Revenue ($m), 2005–2010
Figure 7: HPV Therapeutics Market, France, Forecasts ($m), 2010–2017
Figure 8: HPV Therapeutics Market, Germany, Revenue ($m), 2005–2010
Figure 9: HPV Therapeutics Market, Germany, Forecast ($m), 2010–2017
Figure 10: HPV Therapeutics Market, Italy, Revenue ($m), 2005–2010
Figure 11: HPV Therapeutics Market, Italy, Forecast ($m), 2010–2017
Figure 12: HPV Therapeutics Market, Spain, Revenue ($m), 2005–2010
Figure 13: HPV Therapeutics Market, Spain, Forecast ($m), 2010–2017
Figure 14: HPV Therapeutics Market, The UK, Revenue ($m), 2005–2010
Figure 15: HPV Therapeutics Market, The UK, Forecasts ($m), 2010–2017
Figure 16: HPV Therapeutics Market, Japan, Revenue ($m), 2005–2010
Figure 17: HPV Therapeutics Market, Japan, Forecasts 2010–2017
Figure 18: Opportunity and Unmet Need in the HPV Prophylactic Market, 2010
Figure 19: Opportunity and Unmet Need in the HPV Therapeutic Market, 2010
Figure 20: HPV Prophylactics Market, Strategic Competitor Assessment, 2010
Figure 21: HPV Therapeutics Market, Strategic Competitor Assessment, 2010
Figure 22: HPV Therapeutics - Aldara Cream, Clinical Trial Details
Figure 23: HPV Therapeutics Market, Pipeline by Phase of Development, 2010
Figure 24: HPV Therapeutics Market, Technology Trends Analytics Framework, 2010
Figure 25: HPV Therapeutics Market, Technology Trends Analytics Framework, Description, 2010
Figure 26: HPV Therapeutics Market, Pipeline by Mechanism of Action (%), 2010
Figure 27: HPV Therapeutics Market, Number of Clinical Trials by Country, 2010
Figure 28: HPV Therapeutics Market, Clinical Trials by Phase (%), 2010
Figure 29: HPV Therapeutics Market, Clinical Trials by Status (%), 2010
Figure 30: HPV Therapeutics Market, Overall Sponsors (%), 2010
Figure 31: HPV Therapeutics Market, Prominent Sponsors (%), 2010
Figure 32: HPV Therapeutics Market, Top Companies Participating in Therapeutics Clinical Trials, 2010
Figure 33: HPV Therapeutics Market, Drivers and Restraints 2010
Figure 34: HPV Prophylactic Market, Implications for Future Market Competition, 2010
Figure 35: HPV Therapeutics Market, Implications for Future Market Competition, 2010
Figure 36: HPV Therapeutics Market, Pipeline by Company, 2010
Figure 37: GlobalData Market Forecasting Model
COMPANIES MENTIONED
Merck & Co
GlaxoSmithKline plc
F. Hoffmann-La Roche Ltd.
Inovio Pharmaceuticals,Inc
1.1 List of Tables
1.2 List of Figures
2 HPV THERAPEUTICS - INTRODUCTION
2.1 Disease Overview
2.1.1 Common warts
2.1.2 Laryngeal papilloma
2.1.3 Genital warts
2.1.4 Cervical cancer
2.2 Epidemiology
2.3 Etiology and Pathophysiology
2.4 Signs and Symptoms
2.5 Diagnosis
2.5.1 Pap smear
2.5.2 Colposcopy
2.5.3 Biopsy
2.5.4 Human papillomavirus test
2.6 Treatment and Management Options
2.6.1 Prophylactic vaccines
2.6.2 Genital Warts and common warts treatments
2.6.3 Cervical cancer treatments
2.7 GlobalData Pipeline Report Guidance
3 HPV THERAPEUTICS - MARKET CHARACTERIZATION
3.1 HPV Therapeutics Market Size (2005-2010) – Global
3.2 HPV Therapeutics Market Forecast (2010-2017) – Global
3.3 HPV Therapeutics Market Size (2005–2010) – The US
3.4 HPV Therapeutics Market Forecast (2010-2017) – The US
3.5 HPV Therapeutics Market Size (2005–2010) – France
3.6 HPV Therapeutics Market Forecast (2010–2017) – France
3.7 HPV Therapeutics Market Size (2005–2010) – Germany
3.8 HPV Therapeutics Market Forecast (2010–2017) – Germany
3.9 HPV Therapeutics Market Size (2005–2010) – Italy
3.10 HPV Therapeutics Market Forecast (2010-2017) – Italy
3.11 HPV Therapeutics Market Size (2005–2010) – Spain
3.12 HPV Therapeutics Market Forecast (2010–2017) – Spain
3.13 HPV Therapeutics Market Size (2005–2010) – The UK
3.14 HPV Therapeutics Market Forecast (2010–2017) – The UK
3.15 HPV Therapeutics Market Size (2005–2010) – Japan
3.16 HPV Therapeutics Market Forecast (2010-2017) – Japan
3.17 Drivers and Barriers for the HPV Therapeutics Market
3.17.1 Barriers for the HPV Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway
4 HPV THERAPEUTICS - COMPETITIVE ASSESSMENT
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the HPV Therapeutics Market
4.3.1 Prophylactic Vaccines
4.3.2 Comparison between Cervarix and Gardasil
4.3.3 Therapeutic Drugs
4.3.4 Aldara (imiquimod, 5%)
4.3.5 Veregen (sinecatechin)
4.3.6 Alferon N (interferon alfa-n3)
4.4 Newly Approved Drug
4.4.1 Zyclara (imiquimod, 3.75%)
5 HPV THERAPEUTICS - PIPELINE ASSESSMENT
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 HPV Therapeutics Pipeline – Pipeline by Phases of Development
5.3.1 HPV Therapeutics – Phase III Pipeline
5.3.2 HPV Therapeutics – Phase II Pipeline
5.3.3 HPV Therapeutics – Phase I Pipeline
5.3.4 HPV Market – Discovery and Pre-Clinical Pipeline
5.3.5 Technology Trends Analytic Framework
5.4 HPV Therapeutics Market – Clinical Pipeline by Mechanism of Action
5.5 HPV Therapeutics – Promising Drugs Under Clinical Development
5.6 Molecule Profile for Promising Drugs Under Clinical Development
5.6.1 V503
5.6.2 R3484
5.7 Key Takeaway
6 HPV THERAPEUTICS - CLINICAL TRIALS MAPPING
6.1 Clinical Trials by Region/Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in HPV Therapeutics Clinical Trials
7 HPV THERAPEUTICS - STRATEGIC ASSESSMENT
7.1 Key Events Impacting the Future Market
7.2 HPV Therapeutics: Implications for Future Market Competition
8 HPV THERAPEUTICS - FUTURE PLAYERS
8.1 Introduction
8.2 Company Profiles
8.2.1 Merck & Co
8.2.2 GlaxoSmithKline plc
8.2.3 F. Hoffmann-La Roche Ltd.
8.2.4 Inovio Pharmaceuticals,Inc
9 HPV THERAPEUTICS - LICENSING AND PARTNERSHIP DEALS
10 HPV THERAPEUTICS - APPENDIX
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography
LIST OF TABLES
Table 1: Types Of HPV Causing Different Diseases
Table 2: Cervical Cancer Treatment by Stage of the Disease, 2010
Table 3: HPV Therapeutics Market, Global, Revenue ($m) 2005–2010
Table 4: HPV Therapeutics Market, Global, Forecast ($m), 2010–2017
Table 5: HPV Therapeutics Market, The US, Revenue ($m), 2005–2010
Table 6: HPV Therapeutics Market, The US, Forecasts ($m), 2010–2017
Table 7: HPV Therapeutics Market, France, Revenue ($m), 2005–2010
Table 8: HPV Therapeutics Market, France, Forecasts ($m), 2010–2017
Table 9: HPV Therapeutics Market, Germany, Revenue ($m), 2005–2010
Table 10: HPV Therapeutics Market, Germany, Forecasts ($m), 2010–2017
Table 11: HPV Therapeutics Market, Italy, Revenue ($m), 2005–2010
Table 12: HPV Therapeutics Market, Italy, Forecasts ($m), 2010–2017
Table 13: HPV Therapeutics Market, Spain, Revenue ($m), 2005–2010
Table 14: HPV Therapeutics Market, Spain, Forecasts ($m), 2010–2017
Table 15: HPV Therapeutics Market, The UK, Revenue ($m), 2005–2010
Table 16: HPV Therapeutics Market, The UK, Forecasts ($m) 2010–2017
Table 17: HPV Therapeutics Market, Japan, Revenue ($m), 2005–2010
Table 18: HPV Therapeutics Market, Japan, Forecasts ($m), 2010–2017
Table 19: Gardasil Approvals and Fillings
Table 20 : Comparison Of Cervarix And Gardasil
Table 21: Zyclara, Clinical Trial Details, Complete Clearance of External Genital Warts Within 16 Weeks of Treatment (%)
Table 22: Zyclara, Clinical Trial Details, Complete Clearance of External Genital Warts Within 16 Weeks of Treatment by Gender (%), Combined Study
Table 23: HPV Therapeutics Market, Phase III Clinical Pipeline, 2010
Table 24: HPV Therapeutics Market, Phase II Clinical Pipeline, 2010
Table 25: HPV Therapeutics Market, Phase I Clinical Pipeline, 2010
Table 26: HPV Therapeutics Market, Discovery and Pre-Clinical Pipeline, 2010
Table 27: HPV Therapeutics Market, Most Promising Drugs Under Clinical Development, 2010
Table 28: HPV Therapeutics Market, Number of Clinical Trials by Country, 2010
Table 29: HPV Therapeutics Market, Number of Clinical Trials by Phase, 2010
Table 30: HPV Therapeutics Market, Number of Clinical Trials by Status, 2010
Table 31: HPV Therapeutics Market, Number of Prominent Sponsors, 2010
Table 32: HPV Therapeutics Market, Top Companies Participating in Therapeutics Clinical Trials, 2010
Table 33: Merck &Co Infectious Diseases, Pipeline, 2010
Table 34: Merck &Co, Inc – Deals
Table 35: GlaxoSmithKline Plc. – Infectious Diseases, Pipeline, 2010
Table 36: GlaxoSmithKline Plc. Deals, Alliances and Partnerships , 2010-2011
Table 37: F. Hoffmann-La Roche Ltd ,Infectious Disease Pipeline, 2010
Table 38: F. Hoffmann-La Roche Ltd Deals, Alliances and Partnerships , 2010-2011
Table 39: Inovio Pharmaceuticals –Infectious Disease, Pipeline, 2010
Table 40: Inovio Pharmaceuticals, Inc. – Deals
Table 41: HPV Therapeutics Market, Global, Deals, 2010
LIST OF FIGURES
Figure 1: Pathophysiology of HPV
Figure 2: HPV Therapeutics Market, Global, Revenue ($m), 2005–2010
Figure 3: HPV Therapeutics Market, Global, Forecasts ($m), 2010–2017
Figure 4: HPV Therapeutics Market, The US, Revenue ($m), 2005–2010
Figure 5: HPV Therapeutics Market, The US, Forecasts ($m), 2010–2017
Figure 6: HPV Therapeutics Market, France, Revenue ($m), 2005–2010
Figure 7: HPV Therapeutics Market, France, Forecasts ($m), 2010–2017
Figure 8: HPV Therapeutics Market, Germany, Revenue ($m), 2005–2010
Figure 9: HPV Therapeutics Market, Germany, Forecast ($m), 2010–2017
Figure 10: HPV Therapeutics Market, Italy, Revenue ($m), 2005–2010
Figure 11: HPV Therapeutics Market, Italy, Forecast ($m), 2010–2017
Figure 12: HPV Therapeutics Market, Spain, Revenue ($m), 2005–2010
Figure 13: HPV Therapeutics Market, Spain, Forecast ($m), 2010–2017
Figure 14: HPV Therapeutics Market, The UK, Revenue ($m), 2005–2010
Figure 15: HPV Therapeutics Market, The UK, Forecasts ($m), 2010–2017
Figure 16: HPV Therapeutics Market, Japan, Revenue ($m), 2005–2010
Figure 17: HPV Therapeutics Market, Japan, Forecasts 2010–2017
Figure 18: Opportunity and Unmet Need in the HPV Prophylactic Market, 2010
Figure 19: Opportunity and Unmet Need in the HPV Therapeutic Market, 2010
Figure 20: HPV Prophylactics Market, Strategic Competitor Assessment, 2010
Figure 21: HPV Therapeutics Market, Strategic Competitor Assessment, 2010
Figure 22: HPV Therapeutics - Aldara Cream, Clinical Trial Details
Figure 23: HPV Therapeutics Market, Pipeline by Phase of Development, 2010
Figure 24: HPV Therapeutics Market, Technology Trends Analytics Framework, 2010
Figure 25: HPV Therapeutics Market, Technology Trends Analytics Framework, Description, 2010
Figure 26: HPV Therapeutics Market, Pipeline by Mechanism of Action (%), 2010
Figure 27: HPV Therapeutics Market, Number of Clinical Trials by Country, 2010
Figure 28: HPV Therapeutics Market, Clinical Trials by Phase (%), 2010
Figure 29: HPV Therapeutics Market, Clinical Trials by Status (%), 2010
Figure 30: HPV Therapeutics Market, Overall Sponsors (%), 2010
Figure 31: HPV Therapeutics Market, Prominent Sponsors (%), 2010
Figure 32: HPV Therapeutics Market, Top Companies Participating in Therapeutics Clinical Trials, 2010
Figure 33: HPV Therapeutics Market, Drivers and Restraints 2010
Figure 34: HPV Prophylactic Market, Implications for Future Market Competition, 2010
Figure 35: HPV Therapeutics Market, Implications for Future Market Competition, 2010
Figure 36: HPV Therapeutics Market, Pipeline by Company, 2010
Figure 37: GlobalData Market Forecasting Model
COMPANIES MENTIONED
Merck & Co
GlaxoSmithKline plc
F. Hoffmann-La Roche Ltd.
Inovio Pharmaceuticals,Inc
